Bell Potter maintains a buy rating on MedAdvisor (ASX:MDR) and has a 12-month price target of $0.64. The buy rating is maintained by Bell Potter following another strong quarter of topline growth in the US, Australia and New Zealand, while gross margins also improved. Q4 revenue was up 32% on the previous corresponding period with full-year revenue up 25%, hence the buy rating is maintained.
Ann: Q4 FY24 MDR Quarterly Update, page-8
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
0.015(6.00%) |
Mkt cap ! $146.0M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 29.0¢ | 25.5¢ | $308.5K | 1.150M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3205 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 35907 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MDR (ASX) Chart |